Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Intelligence

Set Alert for Market Intelligence

UK Pregabalin Prices Skyrocket In May

Pregabalin topped our table of Biggest Risers in May, in another month of multiple treble-digit-percentage average price increases for the UK generics market.

Generic Drugs Pricing Strategies

UK Generic Price Spikes Ease In April

With UK shortages and price rises making headlines in early 2024, April’s generic pricing data suggested an easing of pricing increases, according to the latest figures from WaveData.

Market Intelligence Generic Drugs

Taking European Biosimilars To The Next Level

Europe’s biosimilars market now has many years of progress under its belt. But how can this successful foundation be built upon to make the most of the opportunities on the horizon and achieve even greater access and uptake? In an exclusive interview, Generics Bulletin talks to Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil about the next steps.

Biosimilars Europe

Cigna Move Offers More Good News For US Humira Biosimilars

Cigna’s Evernorth has announced plans to make a Humira biosimilar available for $0 out-of-pocket for Accredo patients from June, adding to momentum for adalimumab rivals from previous policy changes made by CVS in recent weeks. Meanwhile, AbbVie has offered the latest on how competition to its once top-selling brand is ramping up.

Biosimilars Market Intelligence

The Comeback Begins? Positive Signs Seen For Humira Biosimilars In US

After getting off to a slow start last year, US biosimilar rivals to Humira are beginning to gain more traction. Sandoz is increasing its share on a weekly basis, Alvotech and Teva have struck a deal for their newly-approved interchangeable 100mg/ml biosimilar, and the latest market data shows biosimilars capturing twice as much of the market in Q1 as in Q4 2023.

Biosimilars United States

Biosimilars Council Calls Out PBMs For Suppressing Humira Biosimilars Adoption

 The US off-patent association published an analysis of IQVIA data, which highlights the role of rebate schemes that is slowing the adoption of Humira biosimilars that would save billions of dollars.

Biosimilars Advertising, Marketing & Sales

Vardenafil Vaults To The Top Of UK Price Rises In March

Price increases from multiple suppliers pushed vardenafil to the top of our Biggest Risers table for March 2024.

Market Intelligence Pricing Strategies

‘Parity To The Originator Is Not Enough’ – Cardinal Health Talks US Biosimilars

Following what Cardinal Health described as “a year of monumental developments in biosimilars,” the firm’s director of biosimilars, Dracey Poore, spoke to Generics Bulletin for an exclusive Q&A.

Biosimilars United States

Multiple UK Generics See Triple-Digit Rises In February

A raft of different generics saw their average UK trade price more than double in February 2024, according to the latest figures from market researcher WaveData.

Market Intelligence Pricing Strategies

Azithromycin Leads Off UK Rises In January

Azithromycin topped our rundown of the steepest UK generic trade price rises in January 2024, based on figures from WaveData.

Market Intelligence Generic Drugs

Long-Term Biosimilar Sustainability Is At A Tipping Point, Report Says

The current cost-saving benefits of biosimilars may soon be overturned by an unsustainable system that favors originator drugs, lower profits, and increased discounts, according to a new report.

Market Intelligence Biosimilars

AbbVie Sets Out Expectations For 2024 Humira Competition

As AbbVie reported fourth-quarter and full-year results for 2023, the firm set out its expectations for adalimumab biosimilar competition to Humira in the year ahead, particularly in the US.

Market Intelligence Biosimilars

Generics Bulletin Explains: One Year On, US Humira Biosimilars Continue To Struggle For Share

A year to the day since the launch of the first US rival to Humira, adalimumab biosimilars are still struggling to gain a significant foothold in the market. Generics Bulletin looks at the reasons why.

Biosimilars United States

Five-Year LOE Impact Approaches $200bn

As a number of major brands face generic and biosimilar competition, the loss-of-exclusivity impact across the leading 10 developed markets will approach $200bn over the next five years, according to a fresh medicines spending report running to 2028.

Generic Drugs Biosimilars

Coherus And Formycon’s Ranibizumab Rapidly Ramps Up In US

Formycon has reported positive uptake trends in the US for its Coherus-partnered ranibizumab biosimilar at the end of 2023, mirroring recent success in the UK with marketing ally Teva.

Biosimilars United States

Samsung Bioepis Biosimilars Report Slams ‘Stagnant’ US Adalimumab Uptake

In its latest biosimilar market report, Samsung Bioepis laments the lack of uptake for biosimilar rivals to Humira, despite a slew of challengers arriving in the US last year.

Biosimilars Market Intelligence
See All